Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy

International Archives of Allergy and Immunology

Volumn 157, Issue 2, 2012, Pages 136-146

  Grundström, Jeanette ^a   Neimert Andersson, Theresa ^a   Kemi, Cecilia ^b   Nilsson, Ola B ^a   Saarne, Tiiu ^a   Andersson, Mats ^c   Van Hage, Marianne ^a   Gafvelin, Guro ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Viscogel AB   (Sweden)

Author keywords

Allergen specific immunotherapy; Cat allergy; Fel d 1; Mouse model; Vitamin D3

Indexed keywords

ANTIALLERGIC AGENT; CALCITRIOL; CYTOKINE; IMMUNOGLOBULIN G; RECOMBINANT ALLERGEN; RECOMBINANT FEL D 1; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT ALLERGY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; LUNG LAVAGE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH2 CELL;

ALLERGENS; ANIMALS; ANTIBODIES, BLOCKING; BRONCHOALVEOLAR LAVAGE; CATS; CHEMOTAXIS, LEUKOCYTE; CHOLECALCIFEROL; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; SPLEEN;

EID: 80053486806     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000327546     Document Type: Article

References (56)

1. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
2. Nanda A, O'Connor M, Anand M, Dreskin SC, Zhang L, Hines B, Lane D, Wheat W, Routes JM, Sawyer R, Rosenwasser LJ, Nelson HS: Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114: 1339-1344. (Pubitemid 39575887)
3. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163: 2944-2952. (Pubitemid 29399227)
4. Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112: 915-922. (Pubitemid 37412059)
5. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-4194.
6. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O: Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27: 1007-1015.
7. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10. and TGF cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-1214. (Pubitemid 36609138)
8. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111: 1255-1261. (Pubitemid 36683679)
9. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252-3259. (Pubitemid 38263717)
10. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific Tcell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120: 707-713. (Pubitemid 47320765)
11. Windom HH, Lockey RF: An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8: 571-576.
12. Terada T, Zhang K, Belperio J, Londhe V, Saxon A: A chimeric human-cat Fcgamma-Fel d 1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d 1, the major cat allergen. Clin Immunol 2006; 120: 45-56. (Pubitemid 43903384)
13. Hulse KE, Reefer AJ, Engelhard VH, Satinover SM, Patrie JT, Chapman MD, Woodfolk JA: Targeting Fel d 1 to Fc RI induces a novel variation of the T(H)2 response in subjects with cat allergy. J Allergy Clin Immunol 2008; 121: 756-762, e754.
14. Martinez-Gomez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, Crameri R, Kundig TM: Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009; 64: 172-178.
15. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, Saudan P, Bachmann MF: Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206: 1941-1955.
16. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109: 455-462. (Pubitemid 34234196)
17. Mo JH, Park SW, Rhee CS, Takabayashi K, Lee SS, Quan SH, Kim IS, Min IY, Raz E, Lee CH: Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis. Am J Rhinol 2006; 20: 212-218.
18. Neimert-Andersson T, Thunberg S, Swedin L, Wiedermann U, Jacobsson-Ekman G, Dahlen SE, Scheynius A, Gronlund H, van Hage M, Gafvelin G: Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy 2008; 63: 518-526. (Pubitemid 351490401)
19. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B, Bot A, Kundig TM: Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005; 35: 1591-1598.
20. Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout A: J, 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10. and TGF. J Immunol 2008; 180: 5211-5221.
21. Lee SE, Koh YI, Kim MK, Kim YR, Kim SY, Nam JH, Choi YD, Bae SJ, Ko YJ, Ryu HJ, Koh JT, Choy HE, Rhee JH: Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008; 28: 157-165.
22. van Etten E, Mathieu C: Immunoregulation by 1,25-dihydroxyvitamin D3:basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
23. Veldman CM, Cantorna MT, DeLuca HF: Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000; 374: 334-338. (Pubitemid 30120270)
24. Ureta G, Osorio F, Morales J, Rosemblatt M, Bono MR, Fierro JA: Generation of dendritic cells with regulatory properties. Transplant Proc 2007; 39: 633-637. (Pubitemid 46574813)
25. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA: 1,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145: 351-357. (Pubitemid 32825669)
26. Penna G, Adorini L: 1,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-2411. (Pubitemid 30115468)
27. Adorini L, Giarratana N, Penna G: Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004; 16: 127-134. (Pubitemid 38234763)
28. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, Lammas DA, Raza K, Sansom DM: 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183: 5458-5467.
29. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A: In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002; 195: 603-616. (Pubitemid 34461505)
30. Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, Verdino P, Hauswirth A, Liderot K, Valent P, Spitzauer S, Keller W, Valenta R, van Hage-Hamsten M: Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli . J Biol Chem 2003; 278: 40144-40151. (Pubitemid 37248582)
31. Jean J, Turcotte C, Simard RE, Fliss I: Production and characterization of polyclonal antibodies against cholecalciferol (vitamin D3). J Immunol Methods 1999; 223: 155-163. (Pubitemid 29119302)
32. Andersson TN, Ekman GJ, Gronlund H, Buentke E, Eriksson TL, Scheynius A, Van Hage-Hamsten M, Gafvelin G: A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology 2004; 113: 253-259. (Pubitemid 39312453)
33. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93. (Pubitemid 24181058)
34. Saarne T, Neimert-Andersson T, Gronlund H, Jutel M, Gafvelin G, van Hage M: Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66: 255-263.
35. Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L: 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 2000; 28: 575-583. (Pubitemid 30254459)
36. Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W: Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010; 184: 2194-2203.
37. Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, Niederhagen B, Bieber T, Lund K, Novak N: Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126: 638-645, e631.
38. O'Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, Rolland JM, Sandrini A: House dust mite sublingual immunotherapy: the role for transforming growth factor and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180: 936-947.
39. Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R: TH2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol 2001; 107: 647-653. (Pubitemid 32397752)
40. Gardner LM, O'Hehir RE, Rolland JM: High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN + T cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol 2004; 133: 1-13. (Pubitemid 38199394)
41. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121: 1467-1472, 1472, e1461.
42. Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004; 4: 313-318. (Pubitemid 39006847)
43. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, Valenta R: B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999; 13: 1277-1290. (Pubitemid 29382497)
44. Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95: 577-585.
45. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, Henin D, Benhamou M, Pretolani M, Blank U, Monteiro RC: Identification of Fc RI as an inhibitory receptor that controls inflammation: dual role of FcR ITAM. Immunity 2005; 22: 31-42. (Pubitemid 40143449)
46. Tomassini M, Tsicopoulos A, Tai PC, Gruart V, Tonnel AB, Prin L, Capron A, Capron M: Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 1991; 88: 365-375.
47. Peebles RS, Jr, Liu MC, Adkinson NF, Jr, Lichtenstein LM, Hamilton RG: Ragweedspecific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. J Allergy Clin Immunol 1998; 101: 265-273. (Pubitemid 28152390)
48. Shirinbak S, Taher YA, Maazi H, Gras R, van Esch BC, Henricks PA, Samsom JN, Verbeek JS, Lambrecht BN, van Oosterhout AJ, Nawijn MC: Suppression of th2-driven airway inflammation by allergen immunotherapy is independent of B cell and Ig responses in mice. J Immunol 2010; 185: 3857-3865.
49. Monteiro RC, Van De Winkel JG: IgA Fc receptors. Annu Rev Immunol 2003; 21: 177-204. (Pubitemid 37174530)
50. Takatsu K, Nakajima H: IL-5 and eosinophilia. Curr Opin Immunol 2008; 20: 288-294.
51. Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7-17.
52. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O'Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM: Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116: 146-155. (Pubitemid 43121799)
53. Ranadive NS, Sehon AH: Antibodies to serotonin. Can J Biochem 1967; 45: 1701-1710.
54. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
55. Van Etten E, Decallonne B, Verlinden L, Verstuyf A, Bouillon R, Mathieu C: Analogs of 1.,25-dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem 2003; 88: 223-226.
56. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999; 5: 1339-1345. (Pubitemid 29282937)